Aktuelles

New report: strict regulation of new genomic techniques is scientifically necessary

Environmental impacts of CRISPR/Cas and its challenges for risk assessment

17 March 2020 / In a new report, Testbiotech provides an overview of the latest research developments in environmental risk assessment and new methods of genetic engineering (also known as ‘genome editing’ or ‘new genomic technicques’). The authors come to the conclusion there are imperative scientific reasons for all organisms derived from these new techniques to undergo mandatory risk assessment before they can be released or marketed. Therefore, regulation requirements foreseen by current GMO law in the EU must be mandatory whether or not additional DNA sequences are inserted.

Will there be GMO fast track approvals in the EU?

Testbiotech warns about planned trade deal with the US

9 March 2020 / Testbiotech warned in a letter to the EU Commission against a planned trade agreement between the EU and the Trump administration. The deal might allow fast track approvals for genetically engineered plants. Such plans were reported by the media in Brussels. They would be contrary to the views of many experts in EU member states and independent scientists, who have repeatedly drawn attention to substantial insufficiencies and gaps in current EU risk assessment.

Spreading the risks: when genetically engineered organisms go wild

First scientific review of risks due to offspring of GE plants persisting in natural populations
Wednesday, 4 March 2020

A new peer reviewed paper is published in the international Environmental Sciences Europe journal. The paper addresses specific environmental risks associated with genetically engineered (GE) plants that can spread and propagate in the environment. It is the first publication with a focus on on the risk assessment of so-called next generation effects. The review addresses unintended effects that were observed in spontaneous hybrid offspring but absent in the original plants.

Legal proceedings started against patents on human embryonic stem cells and interventions in the human germ line

Case brought before the German Federal patent court and opposition filed at European Patent Office
Thursday, 20 February 2020

Testbiotech has started legal proceedings in two cases against patents. The cases were initiated to clarify fundamental ethical questions in patent law, especially in regard to the protection of human dignity. A case was filed at the German Federal patent court (Bundespatentgericht) in a bid to nullify the German patent (DE102004062184), which claims uses of human embryos to obtain stem cells.

Pages

Alle | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009